A Phase 4 interventional study of cupping and serkangabin syrup and conventional migraine drug treatment in Migraine Headache, sponsored by Birjand University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-11-24.
Sponsored by Birjand University of Medical Sciences · Phase 4, Interventional, and Treatment
Migraine is the most common recurrent headache. Current therapy of migraine headache consists of multiple drug groups for control of attack and prophylaxis against recurrent attacks. Emerging alternative medicine worldwide led investigators to evaluate the efficacy of cupping therapy plus SERKANGABIN syrup in treatment of migraine headache. Severity, duration and frequency of attacks of migraine headache evaluated in two groups during six months from presentation.
In a randomized controlled trial investigators randomly assigned 76 patients with migraine to cupping therapy plus SERKANGABIN or to receive conventional medical treatment. The use of CAM in migraine is a growing phenomenon. Migraine patients seek and explore both conventional and CAM approaches. Wet cupping is an ancient medical technique still used in several contemporary societies. It is being used in management of hypertension, diabetes mellitus, and headaches, renal and biliary stones and for maintaining health. Little experimental study has been devoted to test its efficacy to treat migraine headache. Investigators planned this study for evaluation of therapeutic efficacy of wet cupping and an Iranian traditional medicine preparation, SERKANGABIN in treatment of migraine headache compared with current medicine protocols. SERKANGABIN is a preparation of honey, vinegar and distilled mint water that in traditional Iranian medicine is believed to have therapeutic effects in many diseases (diabetes mellitus, hypertension, hyperlipidemia, osteoarthritis, chronic obstructive airway disease, interstitial lung disease, hepatitis, fatty liver, ischemic heart disease, migraine, cerebrovascular diseases)
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
This study's enrollment of 391 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →Birjand University of Medical Sciences is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
migraine cases treated by cupping and serkangabin syrup
Procedure: cupping and serkangabin syrup
migraine cases treated by conventional drug treatment protocols
Drug: conventional migraine drug treatment
wet cupping serkangabin syrup
nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
frequency of migraine attacks per week
endpoints evaluated in both study groups 2 weeks after first presentation and receiving treatment protocols
Time frame: 2 weeks after first presentation
severity of migraine attacks
severity of migraine attacks evaluated 2 weeks after first presentation in two study groups
Time frame: 2 weeks after first presentation
duration of migraine attacks
duration of migraine attacks evaluated 2 weeks after first presentationin two study groups
Time frame: 2 weeks after first presentation
severity of migraine attacks
severity of migraine attacks evaluated 1 month after first presentation in two study groups
Time frame: 1 month after first presentation
severity of migraine attacks
severity of migraine attacks evaluated 3 months after first presentation in two study groups
Time frame: 3 months after first presentation
severity of migraine attacks
severity of migraine attacks evaluated 6 months after first presentation in two study groups
Time frame: 6 months after first presentation
duration of migraine attacks
duration of migraine attacks evaluated 1 month after first presentation in two study groups
Time frame: 1 month after first presentation
duration of migraine attacks
duration of migraine attacks evaluated 3 months after first presentation in two study groups
Time frame: 3 months after first presentation
duration of migraine attacks
duration of migraine attacks evaluated 6 months after first presentation in two study groups
Time frame: 6 months after first presentation
frequency of migraine attacks
frequency of migraine attacks evaluated 1 month after first presentation in two study groups
Time frame: 1 month after first presentation
frequency of migraine attacks
frequency of migraine attacks evaluated 3 months after first presentation in two study groups
Time frame: 3 months after first presentation
frequency of migraine attacks
frequency of migraine attacks evaluated 6 months after first presentation in two study groups
Time frame: 6 months after first presentation
The record gives a start of Jun 2008, a primary completion of Sep 2009 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Birjand University of Medical Sciences